GE HealthCare completes recruitment in manganese-based MRI contrast agent study

GE HealthCare has announced, at the European Congress of Radiology, or ECR, in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a manganese-based macrocyclic magnetic resonance imaging, or MRI, contrast agent. Typically, MRI agents – used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue – are gadolinium-based. This manganese-based agent could broaden GE HealthCare’s portfolio of MRI contrast agents available to radiologists, providing a potential alternative in light of perceived concerns relating to gadolinium retention.